Zealand Pharma A/S

ISIN DK0060257814

 | 

WKN A0YJW7

Market cap (in EUR)
3,075 m
Country
Denmark
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
Show more Show less
Healthcare Biopharmaceuticals Other Biopharmaceuticals Denmark

Financials

Key metrics

Market capitalisation, EUR 3,075 m
EPS, EUR 5.22
P/B ratio 1.2
P/E ratio 8.2
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 1,237 m
Net income, EUR 867 m
Profit margin 70.05%

What ETF is Zealand Pharma A/S in?

There are 6 ETFs which contain Zealand Pharma A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Zealand Pharma A/S is the Vanguard FTSE Developed Europe Small-Cap UCITS ETF EUR Dist.
ETF Weight Investment focus Fund size (in m EUR)
Vanguard ESG Developed Europe All Cap UCITS ETF (EUR) Distributing 0.03%
Equity
Europe
Social/Environmental
37
iShares STOXX Europe 600 Health Care UCITS ETF (DE) 0.14%
Equity
Europe
Health Care
730
Vanguard FTSE Global Small-Cap UCITS ETF USD Dist 0.03%
Equity
World
Small Cap
11
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
560
Vanguard FTSE Global All-Cap UCITS ETF USD Dist 0.00%
Equity
World
142
Vanguard FTSE Developed Europe Small-Cap UCITS ETF EUR Dist 0.22%
Equity
Europe
Small Cap
1
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.